Creutzfeldt-Jakob Disease in Brunei Darussalam: Challenges in Diagnosis and Public Health Response

Abstract

Creutzfeldt-Jakob Disease (CJD), a rare and fatal neurodegenerative disorder caused by prions, presents unique challenges in diagnosis and public health response, particularly in small nations such as Brunei Darussalam. With limited healthcare infrastructure for rare diseases and a lack of specialized diagnostic tools, identifying CJD in this context is often delayed, exacerbating patient outcomes and posing risks of transmission in cases of iatrogenic spread. This article explores the situational context of CJD in Brunei Darussalam, reviews global literature on the disease, and discusses the etiology, including potential autoimmune associations and speculative links to vaccines. The discussion highlights significant gaps in surveillance, diagnostic capabilities, and public health measures in Brunei, while offering targeted recommendations for improving detection, education, and response mechanisms. The paper underscores the need for international collaboration and resource allocation to address the challenges of managing CJD in resource-limited settings.

Introduction

Creutzfeldt-Jakob Disease (CJD) is a rare, degenerative, and invariably fatal neurological disorder belonging to the family of transmissible spongiform encephalopathies (TSEs). Characterized by rapidly progressive dementia, motor dysfunction, and behavioral changes, CJD is caused by the accumulation of misfolded prion proteins in the brain, leading to spongiform changes and neuronal loss. The disease manifests in several forms: sporadic (sCJD), genetic (gCJD), iatrogenic (iCJD), and variant (vCJD), the latter linked to bovine spongiform encephalopathy (BSE) exposure. Globally, the incidence of CJD is estimated at 1-2 cases per million population annually, with most cases being sporadic in nature (Uttley et al., 2020).

In Brunei Darussalam, a small Southeast Asian nation with a population of approximately 450,000, the burden of rare diseases like CJD remains poorly documented. The country faces unique challenges in healthcare delivery due to its size, limited specialized medical facilities, and dependence on international collaboration for advanced diagnostics. The rarity of CJD, coupled with non-specific early symptoms, often results in misdiagnosis or delayed confirmation, potentially increasing risks of transmission through medical procedures or contaminated instruments. Additionally, public health responses to such rare conditions are often under-prioritized in national health agendas, further compounding the issue.

This article aims to analyze the challenges in diagnosing and managing CJD in Brunei Darussalam, drawing on global literature to contextualize these challenges within the broader understanding of the disease. It examines the etiology of CJD, including speculative discussions on autoimmune links and vaccine associations, while providing recommendations for strengthening public health frameworks to address this fatal condition. The paper targets healthcare policymakers, clinicians, and public health officials to raise awareness and advocate for improved systems in managing rare neurodegenerative diseases in small nations.

Situational Analysis

Brunei Darussalam operates a centralized healthcare system under the Ministry of Health, providing universal coverage to its citizens. The system includes primary, secondary, and tertiary care, with the Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital serving as the main tertiary referral center. Despite this infrastructure, the capacity for diagnosing and managing rare diseases like CJD is limited. Neurological expertise and advanced diagnostic tools, such as cerebrospinal fluid (CSF) testing for 14-3-3 protein or real-time quaking-induced conversion (RT-QuIC), are not widely available locally. Suspected cases often require samples to be sent abroad for confirmation, leading to diagnostic delays.

There are no publicly documented cases of CJD in Brunei Darussalam to date, which may reflect under-diagnosis rather than absence of the disease. The lack of mandatory reporting for CJD and limited surveillance systems for rare diseases contribute to this data gap. Clinicians in Brunei may also lack familiarity with CJD due to its rarity, often mistaking early symptoms—such as memory loss and behavioral changes—for more common conditions like Alzheimer’s disease or psychiatric disorders. Furthermore, cultural attitudes toward mental health and stigma associated with neurological decline may deter families from seeking timely medical intervention, further complicating early detection.

Public health response mechanisms for CJD in Brunei are also underdeveloped. There are no specific guidelines for handling suspected CJD cases, particularly concerning infection control to prevent iatrogenic transmission through contaminated surgical instruments or blood products. The absence of a national prion disease registry or collaboration with international surveillance networks, such as the European Creutzfeldt-Jakob Disease Surveillance Network (EuroCJD), limits Brunei’s ability to track and respond to potential cases effectively.

Literature Review

Globally, CJD remains a significant public health concern despite its rarity, primarily due to its fatal prognosis and potential for iatrogenic transmission. Sporadic CJD, accounting for approximately 85% of cases, occurs without a clear cause, while genetic forms are associated with mutations in the PRNP gene coding for prion protein (Creutzfeldt–Jakob Disease, 2025). Variant CJD, linked to the consumption of BSE-contaminated beef, emerged in the 1990s, highlighting the zoonotic potential of prion diseases (Will et al., 2019). Iatrogenic CJD, though rare, has been documented through contaminated medical equipment, dura mater grafts, and growth hormone derived from human cadavers, underscoring the importance of stringent infection control (Brown et al., 2020).

Diagnosis of CJD is challenging due to its clinical overlap with other dementias and the need for specialized testing. Magnetic resonance imaging (MRI) showing cortical ribboning or basal ganglia hyperintensity, electroencephalography (EEG) revealing periodic sharp wave complexes, and CSF analysis for biomarkers like 14-3-3 and tau proteins are key diagnostic tools (Hermann et al., 2021). However, definitive diagnosis often requires post-mortem brain autopsy to detect spongiform changes and prion protein deposits. Recent advances, such as RT-QuIC, have improved antemortem diagnostic accuracy by detecting prion seeding activity in CSF or nasal swabs (Orrù et al., 2019).

The etiology of CJD centers on prions, infectious proteins that induce misfolding of normal cellular prion proteins (PrP^C) into pathological forms (PrP^Sc). This misfolding process leads to a cascade of neurodegeneration through mechanisms not fully understood. While prions are the primary causative agent, the trigger for sporadic CJD remains elusive, with hypotheses ranging from somatic mutations to environmental exposures (Prusiner, 2018). Regarding autoimmune links, some studies suggest that neuroinflammation and immune dysregulation may play a role in disease progression, though there is no conclusive evidence that CJD is an autoimmune disorder. Elevated cytokines and microglial activation have been observed in CJD patients, indicating an immune response to prion accumulation, but this appears secondary to the pathology rather than causal (Aguzzi & Zhu, 2017).

Speculation about vaccine links to CJD has surfaced in recent years, particularly concerning vaccines potentially contaminated with prion proteins or triggering neuroinflammatory responses. However, no credible evidence supports a causal relationship between vaccination and CJD. The concern largely stems from historical cases of iatrogenic transmission through biologics, such as human-derived growth hormone, rather than modern vaccines, which undergo rigorous safety testing (FDA, 2024). The theoretical risk of prion contamination in vaccine production is negligible due to strict regulatory controls and the use of synthetic or non-human derived components in most vaccines. Nonetheless, public misinformation about vaccines and rare diseases continues to fuel unfounded concerns, necessitating clear communication from health authorities.

Public health responses to CJD vary widely across countries. High-income nations with advanced surveillance systems, such as the United Kingdom and Australia, have established national registries and guidelines for CJD management, including protocols for sterilization of surgical instruments and deferral of blood donors with potential exposure risk (Australian Government Department of Health, 2025). In contrast, low- and middle-income countries often lack such frameworks, mirroring challenges likely faced in Brunei Darussalam. The EuroCJD network exemplifies international collaboration, providing diagnostic support and epidemiological data to member states, a model that could benefit smaller nations through partnerships (ECDC, 2023).

Discussion

The challenges of diagnosing and managing CJD in Brunei Darussalam are multifaceted, encompassing clinical, infrastructural, and systemic barriers. At the clinical level, the rarity of CJD means that most healthcare providers in Brunei may never encounter a case in their careers, leading to a low index of suspicion. Early symptoms such as confusion and ataxia are non-specific and often attributed to more prevalent conditions, delaying referral to specialists. Even when suspicion arises, the absence of in-country facilities for advanced diagnostics like RT-QuIC or specialized neuroimaging limits confirmatory testing. Sending samples overseas, often to laboratories in Singapore or Australia, introduces logistical delays and costs, which may not be feasible for all patients.

From a public health perspective, Brunei faces significant gaps in surveillance and response capacity. Without a national registry or mandatory reporting for CJD, potential cases may go undocumented, hindering epidemiological understanding and policy development. The risk of iatrogenic transmission, though low, cannot be ignored, particularly in the absence of specific infection control guidelines for handling suspected CJD cases during surgery or autopsy. For instance, prions are notoriously resistant to standard sterilization techniques, requiring specialized protocols that may not be implemented in local hospitals due to lack of awareness or resources (Brown et al., 2020).

Regarding etiology, the primary cause of CJD—prion misfolding—is well-established in the literature. Sporadic CJD, the most common form, likely arises from spontaneous misfolding or somatic mutations in the PRNP gene, though exact mechanisms remain unknown (Prusiner, 2018). In Brunei, where no cases are documented, it is unclear whether genetic predispositions, such as those seen in populations with high rates of gCJD due to specific mutations, play a role. Similarly, the risk of vCJD linked to BSE exposure appears minimal, given strict import controls on beef and livestock in Brunei. However, global travel and food supply chains underscore the need for vigilance.

The question of autoimmune links to CJD remains speculative and unsupported by robust evidence. While neuroinflammation is a feature of CJD pathology, it is widely considered a consequence rather than a driver of disease. Studies showing elevated inflammatory markers and immune activation in CJD patients suggest a reactive process to prion-induced damage, not an autoimmune etiology (Aguzzi & Zhu, 2017). Therefore, framing CJD as an autoimmune condition is not appropriate based on current understanding, and research in Brunei or elsewhere should focus on prion-specific mechanisms rather than immune-targeted therapies.

The potential link between vaccines and CJD is another area of public concern but lacks scientific grounding. Historical cases of iatrogenic CJD were associated with contaminated human-derived biologics, not vaccines per se. Modern vaccine production adheres to stringent safety standards, minimizing any theoretical risk of prion contamination (FDA, 2024). In Brunei, where vaccine hesitancy may already be influenced by cultural or misinformation factors, public health messaging must proactively address such concerns to prevent unfounded fears from undermining immunization programs. There is no evidence to suggest that vaccines contribute to CJD incidence in Brunei or globally, and efforts should instead focus on educating the public about the true risks and transmission pathways of prion diseases.

Culturally, Brunei’s close-knit communities and reverence for traditional practices may influence healthcare-seeking behavior for neurological conditions. Stigma around dementia and mental health issues could delay diagnosis, as families may initially seek alternative remedies or avoid medical consultation. Public health campaigns must therefore be culturally sensitive, promoting awareness of CJD as a medical rather than a social or spiritual condition, while encouraging early reporting of symptoms.

Recommendations

To address the challenges of CJD in Brunei Darussalam, a multi-pronged approach targeting diagnostic capacity, surveillance, public health policy, and education is essential. The following recommendations are proposed:

1. Enhance Diagnostic Capacity: Invest in training for neurologists and laboratory technicians on CJD recognition and testing. Establish partnerships with regional diagnostic centers in Singapore or Malaysia for access to RT-QuIC and other advanced tools, reducing delays in confirmation. Long-term, consider equipping RIPAS Hospital with basic CSF biomarker testing capabilities.
2. Develop a National Surveillance System: Create a mandatory reporting framework for suspected CJD cases under the Ministry of Health. Integrate Brunei into international networks like EuroCJD to benefit from shared data and expertise. A national registry for rare neurodegenerative diseases, including CJD, should be prioritized to track incidence and guide policy.
3. Implement Infection Control Guidelines: Formulate and disseminate specific protocols for handling suspected CJD cases, focusing on sterilization of surgical instruments and safe autopsy practices. Train healthcare workers on prion transmission risks and the importance of disposable equipment where feasible.
4. Public Health Education: Launch awareness campaigns tailored to Brunei’s cultural context, emphasizing early symptom recognition and the importance of medical evaluation for dementia-like conditions. Combat misinformation about vaccines and CJD through transparent communication from health authorities.
5. International Collaboration: Seek technical and financial support from organizations like the World Health Organization (WHO) to build capacity for rare disease management. Collaborate with ASEAN neighbors to develop a regional strategy for prion disease surveillance and response.
6. Research and Monitoring: Encourage local research on CJD prevalence and risk factors specific to Brunei, potentially through university-hospital partnerships. Monitor global developments in CJD etiology and diagnostics to adapt best practices locally.

These recommendations require coordinated efforts between government, healthcare providers, and the public, with a focus on balancing resource constraints with the urgency of addressing a fatal condition like CJD.

Conclusion

Creutzfeldt-Jakob Disease, though rare, poses significant diagnostic and public health challenges in Brunei Darussalam due to limitations in healthcare infrastructure, surveillance, and awareness. The disease’s fatal nature and potential for iatrogenic transmission necessitate urgent action to improve detection and response mechanisms. While the etiology of CJD is firmly linked to prions, with no credible evidence supporting autoimmune causation or vaccine associations, public health efforts must address misinformation to maintain trust in healthcare systems. Through enhanced diagnostics, surveillance, infection control, and education, Brunei can build resilience against CJD and other rare diseases. International collaboration offers a critical pathway to overcoming local constraints, ensuring that even small nations are equipped to manage complex health threats. This paper serves as a call to action for policymakers and health professionals in Brunei to prioritize rare disease frameworks, safeguarding public health in an increasingly interconnected world.

References

• Aguzzi, A., & Zhu, C. (2017). Microglia in prion diseases. Journal of Clinical Investigation, 127(9), 3230-3239. https://doi.org/10.1172/JCI90605
• Australian Government Department of Health. (2025). Creutzfeldt–Jakob disease (CJD). Retrieved from https://www.health.gov.au/diseases/creutzfeldt-jakob-disease-cjd
• Brown, P., Brandel, J. P., & Sato, T. (2020). Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerging Infectious Diseases, 26(6), 1070-1081. https://doi.org/10.3201/eid2606.191810
• Creutzfeldt–Jakob Disease. (2025). StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK507860/
• ECDC. (2023). European Creutzfeldt-Jakob Disease Surveillance Network (EuroCJD). Retrieved from https://www.ecdc.europa.eu/en/about-ecdc/what-we-do/partners-and-networks/disease-and-laboratory-networks/european-creutzfeldt
• FDA. (2024). Variant Creutzfeldt-Jakob Disease (vCJD) and Factor VIII (pdFVIII) Questions and Answers. Retrieved from https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/variant-creutzfeldt-jakob-disease-vcjd-and-factor-viii-pdfviii-questions-and-answers
• Hermann, P., Appleby, B., & Brandel, J. P. (2021). Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurology, 20(3), 235-246. https://doi.org/10.1016/S1474-4422(20)30477-4
• Orrù, C. D., Groveman, B. R., & Hughson, A. G. (2019). Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathologica Communications, 7, 7. https://doi.org/10.1186/s40478-018-0657-1
• Prusiner, S. B. (2018). Prions. Proceedings of the National Academy of Sciences, 115(21), 5502-5507. https://doi.org/10.1073/pnas.1806564115
• Uttley, L., Carroll, C., Wong, R., Hilton, D. A., & Stevenson, M. (2020). Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infectious Diseases, 20(1), e2-e10. https://doi.org/10.1016/S1473-3099(19)30615-2
• Will, R. G., Ironside, J. W., & Zeidler, M. (2019). A new variant of Creutzfeldt-Jakob disease in the UK. Lancet, 347(9006), 921-925. https://doi.org/10.1016/S0140-6736(96)91412-9